Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Oxford Cannabinoid Technologies "officially on the way" after first dosing

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after announcing that the company has commenced its phase I clinical trial for the lead drug candidate, OCT461201, marking the administration of the first human dose. Researchers will assess the pain relief treatment's safety, tolerability, and pharmacokinetic profile (how it interacts with the body). Sowemimo-Coker says its "so important to have that significant milestone of finally getting that first dose into a healthy volunteer, so we can officially say we're on the way and looking forward to getting those results over time." The trial holds promise for patients suffering from chemotherapy-induced peripheral neuropathy (CIPN), a condition affecting 60% of chemotherapy recipients, causing severe pain and sensitivity in extremities. Sowemimo-Coker also highlights the recent addition to the team of Dr. Farquhar Smith, who runs the only CIPN clinic in the UK at the Royal Marsden. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 27, 2023 10:39 AM Eastern Daylight Time

Video

Oxford Cannabinoid Technologies first dosing a "major achievement" - Proactive Research Analyst

Oxford Cannabinoid Technologies Holdings PLC

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on Oxford Cannabinoid Technology Holdings PLC. The pharmaceutical group announced on 27 July that it has commenced its phase I clinical trial for lead drug candidate, OCT461201, marking the administration of the first human dose. Appiah describes the news as a "major achievement" for Oxford Cannabinoid Technologies, highlighting its transformation from a development company into being a clinical company He also gives an overview of other recent news from the business. For more details, read Daniel's full report by clicking the link provided. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 27, 2023 10:38 AM Eastern Daylight Time

Video

PathAI Launches its AI-Powered PathExplore Data Access Program for Academic Researchers

PathAI

PathAI, a global leader in AI-powered pathology, today announced it has applied its PathExplore panel of human interpretable features (HIFs) on publicly available samples from The Cancer Genome Atlas (TCGA), a comprehensive resource of oncology data containing genomic and outcomes data, along with associated H&E whole-slide images (WSIs). PathAI will make the HIFs from eight TCGA cancer types available for free as a data access program for academic researchers to perform independent research to support their own investigations. Earlier this year, PathAI launched PathExplore, an AI-powered panel of HIFs offering unprecedented resolution of the tumor microenvironment (TME) from digitized H&E slides. Powered by artificial intelligence, PathExplore spatially characterizes the TME with single-cell resolution, giving researchers the ability to unlock insights on patient response, drug pathways, and potential novel biomarkers. The ability to characterize and quantify histopathological features of the TME will enable new avenues of disease research, and may lead to promising new therapies. With this PathExplore HIF research data set, oncology researchers can analyze tissue compositions, cell populations, and how their quantities and spatial relationships correlate with molecular signatures, treatment response or prognostic outcomes. This data set is the first of its kind: no other widely available quantitative, structured data set based on histopathology exists. The features are standardized across indications, so researchers can glean new insights into the common or distinct TME characteristics of each tumor type or patient subset. Adding structured and standardized pathology data to TCGA enables a new set of multi-model investigations for researchers to pursue, all while lowering the barrier to integrating pathology image data into biomedical research that previously had been restricted to labs that had access to manual pathology analysis. “The TME has been a challenge to fully investigate due to the sheer amount of spatially distributed information contained within it,” said Mike Montalto, PathAI’s chief scientific officer. “Pathologists can assess the specimens and try to estimate how certain cell or tissue growth patterns are present in each patient, but they cannot exhaustively enumerate each and every relevant cell type under the microscope. That is what our PathExplore products provide - they not only accurately identify where each cell is located, but they provide structured and standardized feature tables that can enable next generation pathology research to be performed.” To learn more about PathAI’s PathExplore HIF research data set and apply for access, please reach out to pathexplore.hifs@pathai.com. If approved, there is no cost to academic researchers to access and use these data sets. PathExplore HIFs are for research use only and not for use in diagnostic procedures. Biopharma industry partners interested in purchasing a license to access PathExplore TCGA HIFs may reach out to bd@pathai.com for more information. PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

July 27, 2023 10:00 AM Eastern Daylight Time

DSS, Inc.’s (NYSE American: DSS) Subsidiary Appoints New Chief Investment Officer to Aggressively Develop Mutual Fund Business for Eventual Spinoff

DSS, Inc.

By David Willey, Benzinga DSS Wealth, Inc. has appointed Daniel Lew as its new Chief Investment Officer (CIO) and Portfolio Manager. DSS Wealth is a mutual fund and a wholly-owned subsidiary of DSS, Inc. (NYSE American: DSS), a multinational that looks to increase shareholder value through incubating and spinning off potentially lucrative companies. DSS, Inc. operates around 40 companies through 9 divisions targeted for high-growth potential, including healthcare, real estate and renewable energy. As its new CIO, Lew will manage DSS Wealth's investment strategies, resource allocation, and risk management to achieve clients' financial goals. He has several decades of experience managing investments, as well as in security analysis and institutional client advisory. Senior investment management positions he has held include those at companies like AIG SunAmerica, Strong Capital, John Hsu Capital, Citizens Advisers and Equitable Capital. Along with his management positions, Lew has also consulted for institutional funds at both William M. Mercer and RogersCasey. Lew’s appointment reflects DSS Wealth's commitments both to attracting top talent and to providing their clients with outstanding investment solutions and personalized service. Daniel Lew, said, "I joined DSS Wealth, Inc. with the mission to build a strong, seasoned team that will deliver better fund performance for DSS AmericaFirst Fund shareholders and to grow assets under management. I am excited that the stock market has been strong, largely driven by a select group of the largest stocks (The Magnificent Seven) in the first half, and now we are seeing signs of breadth expanding to undervalued stocks, especially high dividend and smaller caps. Expanding breadth is usually a strong bullish sign that stocks have much further to run. There is currently over $5 trillion in assets sitting in money market funds to add fuel to the fire." Promoting DSS’ Mission As its new Portfolio Manager, Daniel Lew will leverage his wide-ranging industry experience to drive investment decisions and generate superior returns for clients of DSS Wealth. The company also advises DSS AmericaFirst Quantitative Funds, which approaches investing by using a unique quantitative approach that helps the fund achieve its investment goals. Bringing on Lew is a key strategic move to help grow DSS Wealth, even as the confidence of some hedge fund managers has faltered during 2023. The move comes with the objective of positioning Lew and DSS Wealth to aggressively develop in the sector and advance DSS, Inc.’s overall strategy of incubating and spinning off companies. Lew added, "I was attracted to DSS because of the fact that there are many good underlying businesses here with experienced management teams that are in various stages of turnaround and growth. At the right point, executive management is committed to unlocking those values via spinouts, sales, or mergers. The appreciation potential for patient investors is considerable and I'm very excited to be able to play a role in building shareholder value.” Jason Grady, Chief Operating Officer at DSS, Inc., commented on Lew’s appointment, “His extensive experience, track record, impressive credentials, and demonstrated expertise make him an invaluable addition to our firm. We are confident that under his leadership, our investment strategies will deliver exceptional results for our clients.” DSS, Inc. recently confirmed the highly-anticipated spinoff in its biotech subsidiary, Impact Biomedical. Investors will be awarded four shares of Impact for every share they own in DSS once the company is spun off. The decision to spin off Impact is following the major announcement that its subsidiary Global BioLife, Inc. has signed a licensing partnership with ProPhase BioPharma Inc. (NASDAQ: PRPH) to develop two promising therapeutics, Equivir and Linebacker, from Global BioLife. Within the next few fiscal quarters, DSS plans to spin off two other successful subsidiaries, the medical real estate investment trust, AAMI/AMRE, and the financial services company, American Pacific Bancorp. DSS, Inc. may offer risk-tolerant investors an attractive approach to building a diversified portfolio of future stock dividends as the company executes its business plan of periodic subsidiary spinoffs to its shareholders. Learn more about DSS, Inc. by visiting its website. DSS is a multinational company operating businesses within nine divisions: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to enrich the value of its shareholders through calculated IPO spinoffs and a parametric share distribution strategy. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high growth sectors. These companies offer innovative, flexible, and real-world solutions that not only provide mutual benefits for businesses and their customers, but also create sustainable value and opportunity for transformation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details Rick Lutz- TraDigital IR rick@tradigitalir.com Company Website https://www.dssworld.com/

July 27, 2023 09:00 AM Eastern Daylight Time

Preventable Emergency Dental Visits Cost Americans $2 Billion Every Year — Here’s What You Can Do To Better Manage The High Costs of Dental Care

DentalPlans.com

By Rachael Green, Benzinga The end of the COVID-19 public health emergency has triggered many state Medicaid programs to review recipient eligibility for the first time since the pandemic first began — and an estimated 14.2 million people are expected to lose what little dental coverage they have. While the move to disenroll millions of Americans who no longer qualify for benefits might result in temporary cost savings for states, the long-term costs of reducing access to affordable preventative dental care will likely end up far outpacing any initial savings. Dental emergencies can be a very expensive issue that Americans face, costing approximately $2 billion per year, according to a systematic review of emergency department data. It’s also one of the most preventable. The average Medicaid enrollee with five continuous years of preventive care prior to 2019 experienced 43% lower costs than an individual who received no preventive dental care at all. Dental Care Still Costs Americans Billions Even With Insurance The 14 million Americans at risk of losing dental coverage this year are just part of the affordable dental care problem. According to the American Dental Association, the total amount spent on dental expenditures in the United States reached $162 billion in 2021. Less than half of that was covered by insurers, meaning patients had to pay $63 billion in out-of-pocket costs with the remaining $25 billion paid by publicly-funded supplemental programs. Due to budget concerns, more than half of Americans experiencing an oral health problem opt to just delay dental care which can lead to serious health problems. Dental Savings Plans Are An Affordable Alternative To Insurance That Could Put Dental Care Back In Reach For The Uninsured Or Underinsured Dental savings plans are a flexible insurance alternative that allows plan members to access preventive, restorative and even cosmetic dental services at reduced rates. Plan members report an average savings of 50%*. Anyone can sign up at any time and begin using their plan as soon as it activates, typically within 72 hours – though some plans activate in as little as 24 hours – even on large procedures. Unlike dental insurance, which typically caps coverage at $1,000-$1,500 annually, dental savings plans have no annual limits or restrictions based on current health conditions. With the cost of a root canal and crown costing roughly $1,200, it’s easy for traditional dental insurance to be maxed out after just one treatment plan. With dental savings plans, there is no limit to worry about. To use your plan, you simply show your membership card to one of the thousands of participating dentists and specialists nationwide, and you’ll be billed at the special reduced rate offered by your plan. For those who don’t have dental insurance, dental savings plans can help you afford expensive restorative care like root canals, crowns, bridges and dentures. They also include savings on procedures like dental implants, teeth whitening and veneers that are often not covered by insurance – as well as preventative care. Find your perfect plan today at DentalPlans.com, the largest dental plan marketplace with more than 25 plans from the most trusted brands in healthcare. DentalPlans.com makes it easy to find the plan that fits your specific needs. Visit DentalPlans.com and use their guided online plan finder today to get a personalized plan recommendation in minutes. *Discount Health Program consumer and provider surveys indicate average savings of 50%. Savings may vary by provider, location, and plan. All cost averages obtained from DentalPlans.com procedure search tool, and independent research. DentalPlans.com, founded in 1999, is a leading online marketplace for dental savings plans in the U.S., helping more than a million people to affordably access quality healthcare services. Our mission is to empower consumers with the tools, information, and services that they need to live happier, healthier lives. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Matthew Wong matthew.wong@wpromote.com Company Website https://www.dentalplans.com/

July 27, 2023 09:00 AM Eastern Daylight Time

hVIVO CEO reports on "very strong" H1 2023

hVIVO PLC

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after the specialist contract research organisation released a trading update for first half of 2023 - a period he describes as a "very strong six months." Khan gives his highlights from the update, highlighting a 52% year-on-year increase in revenues to £27.3mln. He attributes the growth to improved operational efficiencies and the increasing frequency of large concurrent trials. The company reports cash reserves of £31.3 million, even after paying out a special dividend of £3 million, with an order book of £78 million. Addressing a technical detail, Khan mentioned that the company would now report revenue exclusive of other income to align with industry practice. Despite delays at the Medicines and Healthcare Products Regulatory Agency impacting some UK clinical trials, Khan says that hVIVO has successfully managed the situation through its risk mitigation strategy. For the next six months, hVIVO plans to maintain its growth momentum, with full-year guidance of £53 million in revenue and an ever-expanding order book. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 27, 2023 08:36 AM Eastern Daylight Time

Video

Eco Animal Health Group diversifying its product portfolio

Eco Animal Health Group PLC

ECO Animal Health Group PLC (AIM: EAH) CEO David Hallas speaks to Thomas Warner from Proactive about the company's recent performance and his hopes for its future, during his first interview on the platform. Hallas starts by giving an overview of the business, which specialises in developing, registering and marketing pharmaceutical products for global animal health markets and particularly for pigs and chickens. The company's flagship product Aivlosin is a proprietary, patented medication which is effective against both respiratory and enteric diseases in pigs and poultry is an anti-infective treatment for respiratory and enteric diseases in animals. Over the past year, the company achieved 4% revenue growth, surpassing market expectations. Hallas highlighted strong growth in Latin America and South and Southeast Asia, driven by increasing demand for high-quality white meat. Looking ahead, Eco Animal Health plans to diversify into preventative disease solutions, such as vaccines and monoclonal antibodies, targeting the US market by the end of next year. Hallas also addressed misconceptions, emphasising that the company's growth is not solely reliant on the Chinese market and that a balanced approach of prevention and treatment is essential for success. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 27, 2023 08:23 AM Eastern Daylight Time

Video

Powering Multiple CPG Industries With A 'Secret Sauce': Bioscience Company Reports Its Proprietary Nanotech Improves Taste And Absorption Of Functional Foods & Beverages

Rexis Biotech

By Rachael Green, Benzinga This month, Rexis Biotech, the company behind an innovative new nano fiber technology for creating highly water-soluble infusions from hydrophobic molecules, announced a new partnership with 3Chi, Inc. The partnership makes Rexis the world’s largest hemp-derived cannabis manufacturer and will see 3Chi’s initial order of 1M cans distributed via Rexis’ massive national distribution network. The agreement is the latest in a string of major contracts Rexis has landed this year, and the news comes in the midst of the biotech’s ongoing crowdfunding campaign through WeFunder, where Rexis is seeking to raise equity and awareness of its new technology. Rexis Is Leveraging Its Proprietary Fused Polymorph Nano Fiber Technology To Improve The Quality And Potency Of Consumer Goods Rexis uses a proprietary co-crystal in a patented procedure that creates a completely tasteless and odorless powder for infusing into foods and beverages. Co-crystallization combines two or more molecules into a single stable crystal structure. It’s already being used in the pharmaceutical industry to improve the bioavailability of drugs. But it’s typically been limited to small-scale or specialized production because it’s a complex and expensive process. Trademarked under the name Fused Polymorph Nano Fiber Technology, this advanced co-crystallization platform turns hydrophobic molecules like CBD, THC and many essential vitamins into nanoparticles ranging from 35 to 50 nanometers. For scale, a single viral cell is about 50 to 100 nanometers. This tiny size makes the ingredients easier for the human body to absorb because it is mostly absorbed within the mouth, well before first past digestion. Clinical research has found that CBD processed using Fused Polymorph Nano Fiber Technology TM is more than 48% bioavailable, for example. That’s a substantial improvement over the 6% bioavailability of standard CBD oil. Better bioavailability means more of the active ingredient is actually getting absorbed into the bloodstream. For ingredients like CBD or THC, that can mean a faster onset of effects and the ability to get the effects you need with a lower dose. Rexis says its proprietary nano fibers can be absorbed into the bloodstream more quickly and completely than standard emulsions. They can even adjust the length of the fibers to speed up or slow down the onset/offset timing. CBD oil isn’t the only poorly-absorbed ingredient on the market. Many of the most popular supplements contain hydrophobic vitamins like Vitamin A, C, D, E, and K. Other functional ingredients like caffeine and many of the essential amino acids the body needs to make protein are also hydrophobic. In addition to being poorly absorbed, the amount that actually makes it into the bloodstream can vary depending on a range of factors. That means you can take the exact same dose and get different results. The technology Rexis uses is meant to not only improve those absorption rates but also make them more consistent so that consumers can more reliably predict what dose to take to meet their needs while ensuring taste is retained or improved – this gives the company a potentially large total addressable market spread across multiple industries. Rexis Is Gaining The Attention Of Industry Leaders Across Key Markets Manufacturers are already hopping on board to use this Fused Polymorph Nano Fiber Technology TM in their supplements, beverages, and other consumer products. Rexis says it’s already signed more than $8.35 million worth of contracts in the first half of this year with a range of clients in rapidly growing industries like cannabis, wellness and functional beverages – the company boasts of powering brands like 3Chi and First Person Group thanks to its focus on retaining or improving taste. In addition to the million dollar agreement with 3Chi this month, the company has signed contracts with other cannabis leaders like Happy Valley, Redbud Roots and Nectr. But it’s not just licensing its tech to customers. Rexis is also developing its own line of retail brands and pharmaceuticals to add additional revenue streams and showcase the wide-ranging potential of this technology. Meanwhile, investors have already helped the biotech raise over $260K through its crowdfunding campaign. For investors interested in learning more, check out their WeFunder page. Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in the Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Ryan Erving ryan@rexissystems.com Company Website https://www.rexissystems.com

July 26, 2023 09:25 AM Eastern Daylight Time

Communications, Video, and Technology Accessibility Act Bill (CVTA) Announced before the 33rd Anniversary of the Americans with Disabilities Act (ADA)

Communication Service for the Deaf

Senator Edward J. Markey of Massachusetts announced the Communications, Video, and Technology Accessibility Act Bill (CVTA) this morning before the 33rd anniversary of the Americans with Disabilities Act. Accessibility standards and requirements have not kept pace with advances in communication technology since the 21 st Century Communications and Video Accessibility Act (CVAA) was passed over a decade ago. As such, individuals who rely on closed captioning, audio descriptions, and a wide range of other accessibility features do not have full access to a range of products and services that are integral to our daily lives. The passage of the CVTA Bill will ensure that Deaf and disabled communities have full access to technology in their personal and professional lives by addressing the following: Requiring closed captioning for online video programming, mirroring current televised video programming requirements; Requiring audio description for both online and televised video programming; Directing the FCC to create and update quality standards for video programming accessibility; Requiring video conferencing services to have built-in accessibility features, such as automatic captioning functions, and the ability to connect sign language interpreters and assistive technologies that are designed to increase access for people with disabilities (e.g., refreshable braille displays); Establishing standards for American Sign Language interpretation when provided during video programming; Ensuring Deaf people who use sign language have equitable access to 9-1-1 emergency services through the use of direct video calling or telecommunications relay services; Requiring manufacturers of devices that display video programming, such as televisions and computers, to include features that allow easy activation and customization of closed captioning and audio description preferences; Expanding the contribution base for the Telecommunications Relay Services Interstate Fund to ensure its sustainability; and Empowering the FCC to ensure accessibility regulations keep pace with emerging technologies, such as artificial intelligence and virtual reality platforms. The team at Communication Service for the Deaf (CSD) encourages you to get in touch with your congressional leaders and express your support for the CVTA Bill. Let Your Representatives Know You Support the CVTA You can download one of our letter templates to get started and use the links below to find your Congressional representative(s). Download the template that applies to you Find your representative Learn more about the 21st Century Communications and Video Accessibility Act (CVAA) Learn more about the CVTA Bill “We are committed as an organization to clearly identifying barriers to accessibility wherever they reside and delivering solutions to ensure full inclusion for all as technology evolves and advancements are made,” Chris Soukup, CEO of CSD, shared. “The CVTA Bill supports this important work and advances equitable access to information, communication, and opportunities for deaf and disability communities.” With this legislation in place accessibility standards will catch up with the rapid advancements in communication technology, ensuring that closed captioning, audio descriptions, and other essential features are seamlessly integrated into television programming and online video streaming platforms. Viewers with disabilities will have the power to easily activate and customize their preferred settings, whether on televisions, smartphones, laptops, or tablets, empowering them to engage fully with the content they love. Together, we can secure a brighter future for the Deaf and hard of hearing community, where technology is a tool for empowerment, not exclusion. Support the CVTA Bill and be a part of this inspiring journey toward equality. About Communication Service for the Deaf Communication Service for the Deaf (CSD) is the largest Deaf-led social impact organization in the world. For more than four decades, CSD has been a leader in creating and providing accessible and innovative solutions for the Deaf community. Today, CSD continues its work to create opportunities for personal and economic growth within the Deaf community, specifically addressing leadership and employment. For more information, please visit CSD and follow us on Facebook, Twitter, Instagram, and LinkedIn. Contact Details Communication Service for the Deaf Molly Miller +1 315-679-8948 mmiller@csd.org Company Website https://www.csd.org/

July 25, 2023 02:05 PM Eastern Daylight Time

1 ... 87 88 89 90 91 ... 290